The European Parliament, in its resolution of March 2nd, 2017, on European Union (EU) options for improving access to medicines, called on the Commission to propose legislation on a European system for health technology assessment (HTA) to harmonize transparent HTA criteria to assess the added therapeutic value and relative effectiveness of health technologies compared with the best available alternative (1). In December 2021, the EU-HTA R, formally known as ‘Regulation (EU) 2021/2282 of the European Parliament and of the Council of December 15th, 2021’ (2), on HTA and amending Directive 2011/24/EU (3) was adopted. It entered into force with implementation starting in January 2022 for oncology products and advanced therapeutic medicinal products (ATMP) in January 2028 for orphan designated products and in January 2030 for all products.